JYNT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Joint Corp (JYNT) is not a strong buy for a beginner investor with a long-term horizon at this time. The stock is experiencing bearish technical indicators, weak financial performance, and lacks significant positive catalysts. While analysts maintain a Buy rating, the company's transition to a franchise model and flat sales growth do not currently present a compelling investment case.
The technical indicators for JYNT are bearish. The MACD is negative and expanding downward, the RSI is neutral but leaning toward oversold territory, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its key support level of 8.174, with resistance levels at 9.198 and 9.514.
The company is transitioning to a pure-play franchise model, which could improve long-term profitability. Adjusted EBITDA increased by 13.9% YoY, and the new marketing focus on chiropractic care for pain relief shows early signs of improvement in patient acquisition.
System-wide sales for 2025 were flat, and the company's 2026 guidance reflects limited growth potential. Net income and EPS dropped significantly YoY, and management's pro forma model post-refranchising has been described as 'underwhelming' by analysts. Additionally, the stock shows no significant trading trends from hedge funds or insiders.
In Q4 2025, revenue remained flat YoY, while net income dropped by -136.50% and EPS fell by -138.89%. Gross margin improved slightly to 78.55%, up 4.48% YoY, but overall financial performance was weak.
Roth Capital lowered the price target from $14 to $12 while maintaining a Buy rating. Analysts see long-term upside but are concerned about the company's post-refranchising model and flat sales growth.
